Pipeline — registered trials by phase
Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris
— · Acne Vulgaris · Completed · est. 2009-04-24
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
— · Acne · Completed · est. 2008-11
A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
— · Acne Vulgaris · Completed · est. 2009-06
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
— · Dermatitis, Chronic · Completed · est. 2011-03-01
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
— · Acne Vulgaris · Completed · est. 2010-01-01
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
— · Plaque-Type Psoriasis · Completed · est. 2009-06
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
— · Systemic Lupus Erythematosus · Completed · est. 2015-09-01
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
— · Acne Vulgaris · Completed · est. 2009-06
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
— · Hand Dermatosis · Completed · est. 2009-01
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
— · Acne Vulgaris · Completed · est. 2009-09
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
— · Acne Vulgaris · Completed · est. 2010-04
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
— · Psoriasis · Completed · est. 2007-12
Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne
— · Acne Vulgaris · Completed · est. 2008-08
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
— · Acne Vulgaris · Completed · est. 2011-12-01
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
— · Acne Vulgaris · Completed · est. 2009-12
U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne
— · Acne Vulgaris · Completed · est. 2009-11-20
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
— · Lupus Erythematosus, Discoid · Completed · est. 2011-06
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
— · Diaper Rash · Completed · est. 2010-12
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
— · Systemic Lupus Erythematosus · Completed · est. 2018-06-18
Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
— · Acne Vulgaris · Completed · est. 2009-08
Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris
— · Acne Vulgaris · Completed · est. 2005-08
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
— · Acne Vulgaris · Completed · est. 2009-11
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
— · Acne Vulgaris · Completed · est. 2010-06-26
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
— · Psoriasis · Completed · est. 2012-12-05
Effect of SRT2379 on Endotoxin-Induced Inflammation
— · Sepsis · Completed · est. 2011-04-26
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
— · Shigellosis · Completed · est. 2015-03
A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus
— · Diabetes Mellitus, Type 2 · Completed · est. 2011-10-12
A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects
— · Diabetes Mellitus, Type 2 · Completed · est. 2008-12-22
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
— · Cough, Healthy · Completed · est. 2024-05-02
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
— · Cough · Completed · est. 2018-10-25
A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases
— · Diabetes Mellitus, Type 2 · Completed · est. 2011-11-24
A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
— · Onychomycosis · Completed · est. 2009-12-04
W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
— · Acne Vulgaris · Completed · est. 2010-06-12
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
— · Acne Vulgaris · Completed · est. 2010-04-10
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
— · Cough, Healthy · Completed · est. 2023-10-13
A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers
— · Diabetes Mellitus, Type 2 · Completed · est. 2009-03-27
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers
— · Diabetes Mellitus, Type 2, Healthy Volunteer · Completed · est. 2008-11
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
— · Acne Vulgaris · Completed · est. 2009-12-20
A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects
— · Psoriasis · Completed · est. 2014-07-02
Study of RPT193 in Healthy Adult Male Subjects
— · Healthy Male Subjects · Completed · est. 2023-10-12
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
— · Cough · Completed · est. 2024-08-22
Study to Assess Blood Levels of Itraconazole During a Two-Week Period
— · Healthy · Completed · est. 2008-07
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
— · Healthy · Completed · est. 2021-10-22
A Study of PNT2258 in Patients With Advanced Solid Tumors
— · Cancer, Lymphoma, Prostate Cancer · Completed · est. 2012-04
A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers
— · Acne Vulgaris · Completed · est. 2010-06-26
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
— · Cough · Completed · est. 2024-12-17
A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers
— · Acne Vulgaris · Completed · est. 2010-04-26
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
— · Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis · Completed · est. 2017-07-18
An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
— · Psoriasis · Completed · est. 2005-03
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
— · Diabetes Mellitus, Type 2 · Completed · est. 2010-09-18
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
— · Hyperhidrosis · Completed · est. 2016-12-08
Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
— · Onychomycosis · Completed · est. 2010-02-19
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
— · Carcinoma, Hepatocellular · Completed · est. 2013-05-31
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
— · Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis · Completed · est. 2014-06
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
— · Acne · Completed · est. 2005-07
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
— · Systemic Lupus Erythematosus · Completed · est. 2016-02-23
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
— · Chronic Pruritus, Atopic Dermatitis · Completed · est. 2021-10-04
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
— · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis · Completed · est. 2018-12-06
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
— · Lymphoma, Diffuse Large B-Cell · Completed · est. 2016-07-11
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
— · Psoriasis · Completed · est. 2014-03-12
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
— · Advanced Cancer · Completed · est. 2024-12-31
Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
— · Acne Vulgaris · Completed · est. 2009-03
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
— · Stroke, Neurologic Diseases, General · Completed
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
— · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis · Completed · est. 2012-04
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
— · Lymphoma, Non-Hodgkin's · Completed · est. 2016-08
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
— · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis · Completed · est. 2014-06
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
— · Cough, Refractory Chronic Cough · Active Not Recruiting · est. 2026-06-10
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
— · Acne Vulgaris · Completed · est. 2009-09
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
— · Psoriasis · Completed · est. 2008-12
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
— · Acne Vulgaris · Completed · est. 2010-11-01
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
— · Cough, Refractory Chronic Cough · Completed · est. 2025-12-17
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
— · Systemic Lupus Erythematosus · Completed · est. 2015-02-13
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
— · Alopecia · Completed · est. 2016-03-19
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
— · Lupus Nephritis · Completed · est. 2019-07-25
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
— · Psoriasis · Completed · est. 2010-12
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
— · Acne Vulgaris · Completed · est. 2010-11
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
— · Systemic Lupus Erythematosus · Completed · est. 2016-12-09
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
— · Ichthyosis, Lamellar · Completed · est. 2007-04
A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
— · Acne Vulgaris, Acne · Completed · est. 2009-04
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
— · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · Completed · est. 2021-12-03
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
— · Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome · Completed
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
— · Psoriasis · Completed · est. 2008-10
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
— · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis · Completed · est. 2016-09-12
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
— · Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) · Completed · est. 2016-07-28
Belimumab in Remission of VASculitis
— · Vasculitis · Completed · est. 2017-02-06
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
— · Systemic Lupus Erythematosus · Completed · est. 2015-03
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
— · Eczema · Completed · est. 2012-04-26
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where GSK is lead sponsor; 94 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-10-08Report of foreign issuer
- 6-K2026-10-06Report of foreign issuer
- 6-K2026-10-01Report of foreign issuer
- 6-K2026-09-24Report of foreign issuer
- CERT2026-09-22CERT
- 6-K2026-09-22Report of foreign issuer
- 8-A12B2026-09-158-A12B
- 6-K2026-09-15Report of foreign issuer
- 6-K2026-09-15Report of foreign issuer
- 6-K2026-09-14Report of foreign issuer
- 6-K2026-09-14Report of foreign issuer
- 6-K2026-09-11Report of foreign issuer
- 6-K2026-09-10Report of foreign issuer
- 424B22026-09-10424B2
- 6-K2026-09-10Report of foreign issuer
- 6-K2026-09-09Report of foreign issuer
- 6-K2026-09-09Report of foreign issuer
- FWP2026-09-09FWP
- 424B22026-09-08424B2
- 6-K2026-09-08Report of foreign issuer
- 6-K2026-09-01Report of foreign issuer
- 6-K2026-09-01Report of foreign issuer
- 6-K2026-08-26Report of foreign issuer
- 6-K2026-08-24Report of foreign issuer
- 6-K2026-08-24Report of foreign issuer
- 6-K2026-08-24Report of foreign issuer
- 6-K2026-08-18Report of foreign issuer
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- 13F-HR2026-08-1313F-HR
- 6-K2026-08-13Report of foreign issuer
- 6-K2026-08-11Report of foreign issuer
- 6-K2026-08-03Report of foreign issuer
- 6-K2026-07-30Report of foreign issuer
- 6-K2026-07-28Report of foreign issuer
- 6-K2026-07-28Report of foreign issuer
- 6-K2026-07-28Report of foreign issuer
- 6-K2026-07-24Report of foreign issuer
- 6-K2026-07-24Report of foreign issuer
- 6-K2026-07-22Report of foreign issuer
- 6-K2026-07-20Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.